Literature DB >> 29746413

INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT AT 2-MONTH INTERVALS REDUCES FOVEAL AVASCULAR ZONE ENLARGEMENT AND VISION LOSS IN RADIATION MACULOPATHY: A Pilot Study.

Alejandra Daruich1, Alexandre Matet, Ann Schalenbourg, Leonidas Zografos.   

Abstract

PURPOSE: To evaluate, in eyes with radiation maculopathy, the effect of 2-month-interval anti-vascular endothelial growth factor therapy on best-corrected visual acuity and foveal avascular zone (FAZ) enlargement using optical coherence tomography angiography.
METHODS: Consecutive treatment-naive patients with radiation maculopathy after proton beam irradiation for choroidal melanoma were retrospectively included. Clinical and optical coherence tomography angiography data at baseline and the 6-month visit were recorded. Two independent observers measured FAZ area manually on 3 × 3-mm optical coherence tomography angiography images of the superficial capillary plexus and deep capillary plexus. Patients were encouraged to follow strictly a 2-month-interval intravitreal anti-vascular endothelial growth factor treatment by either bevacizumab or ranibizumab. Findings were analyzed based on the adherence to the treatment scheme.
RESULTS: According to the adherence to the bimonthly anti-vascular endothelial growth factor treatment protocol, patients were categorized into 3 groups: treatment protocol (n = 19, strict adherence), variable intervals (n = 11, intervals other than 2 months), and no treatment (n = 11). The estimated radiation dose to the foveola in each group was 49 ± 16, 46 ± 17, and 46 ± 18 cobalt gray equivalent, respectively (P = 0.85). For the entire cohort, best-corrected visual acuity loss (P < 0.02) and FAZ enlargement (P < 0.0001) were observed over 6 months. Best-corrected visual acuity loss was significantly less pronounced in the treatment-protocol group than in the variable-interval and no-treatment groups (P = 0.007 and P = 0.004). The FAZ enlargement was lower in the treatment-protocol group compared with the variable-interval group for both superficial capillary plexus (P = 0.029) and deep capillary plexus (P = 0.03), and to the no-treatment group for the deep capillary plexus only (P = 0.016).
CONCLUSION: Decrease in best-corrected visual acuity and FAZ enlargement on optical coherence tomography angiography occurred over 6 months in eyes with radiation maculopathy and were significantly reduced under 2-month-interval anti-vascular endothelial growth factor therapy.

Entities:  

Year:  2019        PMID: 29746413     DOI: 10.1097/IAE.0000000000002200

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  5 in total

1.  Postradiation Optic Atrophy Is Associated With Intraocular Pressure and May Manifest With Neuroretinal Rim Thinning.

Authors:  Lauren A Dalvin; Christopher L Deufel; Kimberly S Corbin; Ivy A Petersen; Timothy W Olsen; Gavin W Roddy
Journal:  J Neuroophthalmol       Date:  2021-11-11       Impact factor: 4.415

2.  Longitudinal optical coherence tomography angiography (OCT-A) in a patient with radiation retinopathy following plaque brachytherapy for uveal melanoma.

Authors:  Elaine M Binkley; Michelle R Tamplin; Anthony H Vitale; H Culver Boldt; Randy H Kardon; Isabella M Grumbach
Journal:  Am J Ophthalmol Case Rep       Date:  2022-03-25

3.  Reduced blood flow by laser speckle flowgraphy after 125I-plaque brachytherapy for uveal melanoma.

Authors:  Michelle R Tamplin; Jui-Kai Wang; Anthony H Vitale; Ryuya Hashimoto; Mona K Garvin; Elaine M Binkley; Daniel E Hyer; John M Buatti; H Culver Boldt; Randy H Kardon; Isabella M Grumbach
Journal:  BMC Ophthalmol       Date:  2022-06-28       Impact factor: 2.086

4.  Temporal Relationship Between Visual Field, Retinal and Microvascular Pathology Following 125I-Plaque Brachytherapy for Uveal Melanoma.

Authors:  Michelle R Tamplin; Wenxiang Deng; Mona K Garvin; Elaine M Binkley; Daniel E Hyer; John M Buatti; Johannes Ledolter; H Culver Boldt; Randy H Kardon; Isabella M Grumbach
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-01-04       Impact factor: 4.799

5.  EIGHTEEN-MONTH RESULTS OF INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON VISION AND MICROCIRCULATION IN RADIATION MACULOPATHY.

Authors:  Chiara M Eandi; Maria S Polito; Ann Schalenbourg; Leonidas Zografos
Journal:  Retina       Date:  2021-09-01       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.